Список литературы

Поставить закладку

Абрамова, Т. В. Пузырчатка: иммунопатогенез, диагностика и патогенетическая терапия (клинико-экспериментальное исследование) // Дисс. докт. мед наук. – Москва. 2019. – 270 с.
Дерматология Фицпатрика в клинической практике Т. 1: пер. с англ. / ред. Н. Н. Потекаева и А.Н. Львова. Москва: Издательство Панфилова, 2015. – 1168 с.
Клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. – 5-е изд., перераб. и доп. Москва: Деловой экспресс, 2016. – 768 с.
Колос, Ю. В. Буллезные дерматозы: диагностическое значение определения аутоантител методом иммуноферментного анализа / Ю. В. Колос, А. М. Лукьянов. // Здравооохранение (Минск). – 2014. – № 3. – С. 55– 61.
Махнева, Н. В. О проблемах диагностики и дифференциальной диагностики аутоиммунной пузырчатки / Н. В. Махнева, Е. Б. Давиденко, Л. В. Белецкая // Альманах клинической медицины. – 2014 – № 34. – С. 9– 14.
Махнева, Н. В. Симптом Никольского в клинике аутоиммунных дерматозов // Российский журнал кожных и венерических болезней. – 2008. – № 5. – С. 26– 29.
Пузырчатка / Н. Д. Шеклаков. – Москва: Медгиз, 1961 – 163 с.
Ткаченко, С. Б. Современные методы дифференциальной диагностики истинной (аутоиммунной) пузырчатки и буллезного пемфигоида. / С. Б. Ткаченко, Н. П. Теплюк, М. Т. Миннибаев, А. С. Алленова, А. Г. Куприянова, А. А. Лепехова, П. М. Пятилова // Российский журнал кожных и венерических болезней. – 2015. – № 3. – С. 17–22.
Ahmed, A. R. Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology / A. R. Ahmed, M. Carrozzo, F. Caux et al. // Experimental Dermatology. – 2016. – Vol. 25, N. 11. – Р. 839–846.
Amagai, M. Pemphigus. In: Dermatology. 3rd ed. / J. L. Bolognia, J. L. Jorizzo, J. V. Schaffer. – Philadelphia: Elsevier. – 2012. – Vol. 1. – Р. 469– 471.
Aoki, V. Direct and indirect immunofluorescence / V. Aoki, JX. Jr. Sousa, L. M. Fukumori et al. // Anais Brasileiros de Dermatologia. – 2010. – Vol. 85, N. 4. – Р. 490–500.
Arpita, R. Oral Pemphigus Vulgaris: Case Report / R. Arpita, A. Monica, N. Venkatesh et al. // Ethiopian Journal of Health Sciences. – 2015. – Vol. 25, N. 4. – Р. 367–372.
Atzmony, L. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis / L. Atzmony, E. Hodak, Y. A. Leshem et al. // Journal of the American Academy of Dermatology. – 2015. – Vol. 73, N. 2. – Р. 264–271.
Autоimmune diseases оf the skin Pathоgenesis, Diagnоsis, Management 3rd ed. / M. Hertl. – USA: Springer-Verlag Wien, 2011. – 594 p.
Behzad, M. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris / M. Behzad, C. Möbs, A. Kneisel et al. // British Journal of Dermatology. – 2012. – Vol. 166, N. 4. – Р. 844–852.
Cholera, M. Management of Pemphigus Vulgaris / M. Cholera, N. Chainani-Wu // Advances in Therapy. – 2016. – Vol. 33, N. 6. – Р. 910–958.
Dabbs, D. Diagnostic Immunohistochemistry: theranostic and genomic applications. In: Diagnostic Immunohistochemistry. 4th ed. / D. Dabbs – Philadelphia: Churchill Livingstone Elsevier. – 2014. – Р. 18–21.
Di Zenzo, G. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface / G. Di Zenzo, G. Di. Lullo, D. Corti et al. // Journal of Clinical Investigation. – 2012. – Vol. 122, N. 10. – Р. 3781–3790.
Frew, J. W. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus / J. W. Frew, L. K. Martin, D. F. Murrell // Clinics in Dermatology. – 2011. – Vol. 29, N. 4. – Р. 599–606.
Gach, J. E. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris / J. E. Gach, A. Ilchyshyn // Clinical and Experimental Dermatology. – 2004. – Vol. 29, N. 3. – Р. 271–272.
Ganapati, S. Eponymous Dermatological Signs in Bullous Dermatoses / S. Ganapati // Indian Journal of Dermatology. – 2014. – Vol. 59, N. 1. – Р. 21–23.
Gushi, M. Neonatal pemphigus vulgaris / M. Gushi, Y. Yamamoto, Y. Mine et al. // Journal of Dermatology. – 2008. – Vol. 35, N. 8. – Р. 529–535.
Hertl, M. Pemphigus. S2 guideline for diagnosis and treatment-guided by the European dermatology forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) / M. Hertl, H. Jedlickova, S. Karpati et al. // Journal of the European Academy of Dermatology and Venereology. – 2015. – Vol. 29, N. 3. – Р. 405–414.
Huang, A. Future therapies for pemphigus vulgaris: Rituximab and beyond / A. Huang, R. K. Madan, J. Levitt // Journal of the American Academy of Dermatology. – 2016. – Vol. 74, N. 4. – Р. 746–753.
Joly, P. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel group, open-label randomised trial / P. Joly, M. Maho-Vaillant, C. Prost-Squarcioni et al. // The Lancet. – 2017. – Vol. 389, N. 10083. – Р. 2031–2040.
Joly, P. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus / P. Joly, C. Richard, D. Gilbert et al. // Journal of the American Academy of Dermatology. – 2000. – Vol. 43, N. 4. – Р. 619–626.
Kasperkiewicz, M. Pemphigus / М. Kasperkiewicz, C. T. Ellebrecht, H. Takahashi et al. // Nature Reviews Disease Primers. – 2017. – N. 3. – Р. 17026. doi: 10.1038/nrdp.2017.26
Lai, O. Influence of cigarette smoking on pemphigus – a systematic review and pooled analysis of the literature / O. Lai, A. Recke, D. Zillikens, M. Kasperkiewicz // Journal of the European Academy of Dermatology and Venereology. – 2018. – N. 32. – Р. 1256–1262.
Lakshmi, M. J. D. Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus / M. J. D. Lakshmi, T. J. Jaisankar, M. Rajappa et al. // Journal of the American Academy of Dermatology. – 2017. – Vol. 76, N. 5. – Р. 895–902.
Langenhan, J. Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins / J. Langenhan, J. Dworschak, S. Saschenbrecker et al. // Experimental Dermatology. – 2014. – Vol. 23, N. 4. – Р. 253–259.
Maltzman, J. S. Azathioprine: old drug, new actions / J. S. Maltzman, G. A. Koretzky // Journal of Clinical Investigation. – 2003. – Vol. 111, N. 8. – Р. 1122–1124.
Martin, L. K. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus / L. K. Martin, V. P. Werth, E. V. Villaneuva D. F. Murrell // Journal of the American Academy of Dermatology. – 2011. – Vol. 64, N. 5. – Р. 903–908.
Mindorf, S. Routine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical pemphigus / S. Mindorf, I. M. Dettmann, S. Kruger et al. // Experimental Dermatology. – 2017. – Vol. 26, N. 12. – Р. 1267–1270.
Mustafa, M. B. Oral mucosal manifestations of autoimmune skin diseases / M. B. Mustafa, S. R. Porter, B. R. Smoller, C. Sitaru // Autoimmunity Review. – 2015. – Vol. 14, N. 10. – Р. 930–951.
Ohzono, A. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus / A. Ohzono, R. Sogame, X. Li et al. // British Journal of Dermatology. – 2015. – Vol. 173, N. 6. – Р. 1447–1452.
Oliveira L.A. Desmoglein 1 and 3 Autoantibody Levels in Endemic Pemphigus Foliaceus and Pemphigus Vulgaris from Brazil / L.A. Oliveira, A. Marquart–Filho, G. Trevilato et al. // Clin Lab. – 2016. – Vol. 62, N 7. – P. 1209– 1216.
Olszewska, M. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris / M. Olszewska, Z. Kolacinska-Strasz, J. Sulej et al. // American Journal of Clinical Dermatology. – 2007. – Vol. 8, N. 2. – Р. 85–92.
Payne, A. S. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display / A. S. Payne, K. Ishii, S. Kacir et al. // Journal of Clinical Investigation. – 2005. – Vol. 115, N. 4. – Р. 888–899.
Rao, P. N. Pulse therapy and its modifications in pemphigus: a six-year study / P. N. Rao, T. S. Lakshmi // Indian Journal of Dermatology, Venereology and Leprology. – 2003. – Vol. 69, N. 5. – Р. 329–333.
Ruocco, E. Pemphigus: Associations and management guidelines: Facts and controversies / E. Ruocco, R. Wolf, V. Ruocco et al. // Clinics in Dermatology. – 2013. – Vol. 31, N. 4. – Р. 382–390.
Ruocco, V. Pemphigus vegetans of the folds (intertriginous areas) / V. Ruocco, E. Ruocco, S. Caccavale, A. Gambardella, A. Lo Schiavo // Clinics in Dermatology. – 2015. – Vol. 33, N. 4. – Р. 471–476.
Schmidt E. Mоdern diagnоsis оf autоimmune blistering skin diseases / E. Schmidt, D. Zillikens // Autоimmun. Rev. – 2010. – Vоl. 10. – P. 84–89.
Shah, A. A. Development of a disease registry for autoimmune bullous diseases: initial analysis of the pemphigus vulgaris subset / A. A. Shah, K. Seiffert-Sinha, D. Sirois et al. // Acta Dermato-Venereologica. – 2015. – Vol. 95, N. 1. – P. 86–90.
Sinha, A. A. Pemphigus vulgaris: approach to treatment / A. A. Sinha, M. B. Hoffman, E. C. Janicke // Journal of the European Academy of Dermatology and Venereology. – 2015. – Vol. 25, N. 2. – Р. 103–113.
Sokol, E. Large-scale electron microscopy maps of patient skin and mucosa provide insight into pathogenesis of blistering diseases / E. Sokol, D. Kramer, G. F. H. Diercks et al. // Journal of Investigative Dermatology. – 2015. – Vol. 135, N. 7. – Р. 1763–1770.
Tavakolpour, S. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments? / S. Tavakolpour // International Immunopharmacology. – 2017. – Vol. 53. – Р. 133–142.
Tsunoda, K. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3 / K. Tsunoda, T. Ota, M. Aoki et al. // Journal of Immunology. – 2003. – Vol. 170, N. 4. – Р. 2170–2178.
Van Beek N. Diagnosis of autoimmune bullous diseases / N. Van Beek, D.Zillikens, E. Schmidt // J Dtsch Dermatol Ges. – 2018. – Vol. 16, N 9. – P.1077–1091.
Venugopal, S. S. Diagnosis and clinical features of pemphigus vulgaris / S. S. Venugopal, D. F. Murrell // Clinics in Dermatology. – 2011. – Vol. 29, N. 3. – Р. 373–380.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница